1. Darrow TL, Slingluff CL, Seigler HF (1988) Autologous lymph node cell-derived tumor-specific cytotoxic T-cells for use in adoptive immunotherapy of human melanoma. Cancer 62:84–91
2. Slingluff CL Jr, Darrow TL, Seigler HF (1989) Melanoma-specific cytotoxic T cells generated from peripheral blood lymphocytes. Implications of a renewable source of precursors for adoptive cellular immunotherapy. Ann Surg 210:194–202
3. Yamshchikov G, Thompson L, Ross WG, Galavotti H, Aquila W, Deacon D, Caldwell J, Patterson JW, Hunt DF, Slingluff CL Jr (2001) Analysis of a natural immune response against tumor antigens in a melanoma survivor: lessons applicable to clinical trial evaluations. Clin Cancer Res 7:909s–916s
4. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Sznol M, Schwarz SL, Spiess PJ, Wunderlich JR, Seipp CA, Einhorn JH, Rogers-Freezer L, White DE (1999) Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol 163:1690–1695
5. Slingluff CL Jr, Yamshchikov GY, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Hibbitts S, Teates D, Neese PY, Grosh WW, Petroni GR, Gibson J, Czarkowski AR, Ross M, Engelhard VH, Ross WG (2003) Clinical and immunologic results of a randomized phase II trial of vaccination utilizing four melanoma peptides either administered in GMCSF-in-adjuvant or pulsed on dendritic cells. J Clin Oncol 21:4016–4026